$28.74-0.53 (-1.81%)
Stratus Properties Inc., a real estate company, engages in the entitlement, development, management, leasing, and sale of multi and single family residential and commercial real estate properties in the Austin, Texas area, and other select markets in Texas.
Stratus Properties Inc. in the Real Estate sector is trading at $28.74 with a market capitalization of $222M. The stock is currently 13% below its 52-week high of $32.93, remaining 10.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.79Mβ | $8.30Mβ | $4.97Mβ | $11.61Mβ | $5.04M |
| Gross Profit | -$1.91Mβ | -$981,000β | -$4.23Mβ | -$2.20Mβ | $256,000 |
| Operating Income | -$7.50Mβ | -$4.29Mβ | -$8.09Mβ | -$5.76Mβ | -$3.79M |
| Net Income | $6.63Mβ | $19.57Mβ | -$4.98Mβ | $260,000β | -$2.88M |
Stratus Properties Inc., a real estate company, engages in the entitlement, development, management, leasing, and sale of multi and single family residential and commercial real estate properties in the Austin, Texas area, and other select markets in...
Pfizer, Altria, Newmont, Koil Energy and Stratus Properties are featured for their growth drivers, challenges and recent stock performance.
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Altria Group, Inc. (MO) and Newmont Corp. (NEM), as well as two micro-cap stocks, Koil Energy Solutions, Inc. (KLNG) and Stratus Properties Inc. (STRS).
Vail Resorts operates 37 mountain destinations, combining lift ticket sales, hospitality, and real estate across North America.
STRS posts Q1 earnings per share driven by strong leasing segment gains from asset sales as the company advances its liquidation plan and targets shareholder payouts of up to $37.69 per share.
Eli Lilly leads with strong GLP-1 drug demand and pipeline growth, while Mastercard and AMD navigate rising costs and AI-driven opportunities.